



SAFETY DATA SHEET

Revision date 06-Dec-2021

Version 1.01

Page 1 / 11

Section 1: IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERTAKING

1.1. Product identifier

Product Name Daptomycin for Injection (rapid reconstitution)
Product Code(s) PF00262
Trade Name: Not applicable
Chemical Family: Not determined

1.2. Relevant identified uses of the substance or mixture and uses advised against

Recommended Use Pharmaceutical product used as antibiotic agent

1.3. Details of the supplier of the safety data sheet

Hospira, A Pfizer Company
275 North Field Drive
Lake Forest, Illinois 60045
1-800-879-3477

Hospira UK Limited
Horizon
Honey Lane
Hurley
Maidenhead, SL6 6RJ
United Kingdom

E-mail address pfizer-MSDS@pfizer.com

1.4. Emergency telephone number

Emergency Telephone Chemtrec 1-800-424-9300 International Chemtrec (24 hours):+1-703-527-3887

Section 2: HAZARDS IDENTIFICATION

2.1. Classification of the substance or mixture

GHS - Classification

Specific target organ toxicity (repeated exposure) Category 2 - (H373)

2.2. Label elements

Signal word Warning

Hazard statements H373 - May cause damage to organs through prolonged or repeated exposure

Precautionary Statements P260 - Do not breathe dust/fume/gas/mist/vapors/spray
P314 - Get medical attention/advice if you feel unwell

SAFETY DATA SHEET

Product Name Daptomycin for Injection (rapid reconstitution)
Revision date 06-Dec-2021

Page 2 / 11
Version 1.01

P501 - Dispose of contents/container in accordance with all local and national regulations



2.3. Other hazards

Other hazards

An Occupational Exposure Value has been established for this substance (see Section 8).

Note:

This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

Section 3: COMPOSITION/INFORMATION ON INGREDIENTS

3.1 Substances

Substances

Not applicable

3.2 Mixtures

Hazardous

Chemical name	Weight-%	REACH Registration Number	EC No	Classification according to Regulation (EC) No. 1272/2008 [CLP]	Specific concentration limit (SCL)	M-Factor	M-Factor (long-term)
Daptomycin (CAS #: 103060-53-3)	5 - 10		Not Listed	STOT RE 2 (H373)	Not Listed	No data available	No data available
Sodium hydroxide (CAS #: 1310-73-2)	**	-	215-185-5	Skin Corr.1A (H314)	Eye Irrit. 2 :: 0.5%<=C<2% Skin Corr. 1A :: C>=5% Skin Corr. 1B :: 2%<=C<5% Skin Irrit. 2 :: 0.5%<=C<2%	No data available	No data available
Citric acid (CAS #: 77-92-9)	< 1		201-069-1	Eye Irrit. 2A (H319)SE 3 (H335)	Not Listed	No data available	No data available

Full text of H- and EUH-phrases: see section 16

Acute Toxicity Estimate

Chemical name	Oral LD50	Dermal LD50	Inhalation LC50 - 4 hour - dust/mist - mg/L	Inhalation LC50 - 4 hour - vapor - mg/L	Inhalation LC50 - 4 hour - gas - ppm
Sodium hydroxide 1310-73-2	325	1350	No data available	No data available	No data available

SAFETY DATA SHEET

Product Name Daptomycin for Injection (rapid reconstitution)
Revision date 06-Dec-2021

Page 3 / 11
Version 1.01

Chemical name	Oral LD50	Dermal LD50	Inhalation LC50 - 4 hour - dust/mist - mg/L	Inhalation LC50 - 4 hour - vapor - mg/L	Inhalation LC50 - 4 hour - gas - ppm
Citric acid 77-92-9	5400	>2000	No data available	No data available	No data available

Additional information

** to adjust pH

In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret. Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.

Section 4: FIRST AID MEASURES

4.1. Description of first aid measures

Inhalation	Remove to fresh air. Seek immediate medical attention/advice.
Eye contact	Rinse thoroughly with plenty of water for at least 15 minutes, lifting lower and upper eyelids. Consult a physician.
Skin contact	Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.
Ingestion	Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

4.2. Most important symptoms and effects, both acute and delayed

Most important symptoms and effects For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

4.3. Indication of any immediate medical attention and special treatment needed

Note to physicians None.

Section 5: FIRE-FIGHTING MEASURES

5.1. Extinguishing media

Suitable Extinguishing Media Use carbon dioxide, dry chemical, or water spray.

5.2. Special hazards arising from the substance or mixture

Specific hazards arising from the chemical Fine particles (such as dust and mists) may fuel fires/explosions.

Hazardous combustion products Emits toxic fumes of carbon monoxide, carbon dioxide, and nitrogen oxides.

5.3. Advice for firefighters

Special protective equipment for fire-fighters Firefighters should wear self-contained breathing apparatus and full firefighting turnout gear. Use personal protection equipment.

Section 6: ACCIDENTAL RELEASE MEASURES

6.1. Personal precautions, protective equipment and emergency procedures

SAFETY DATA SHEET

Product Name Daptomycin for Injection (rapid reconstitution)
Revision date 06-Dec-2021

Page 4 / 11
Version 1.01

Personal precautions Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

For emergency responders Use personal protection recommended in Section 8.

6.2. Environmental precautions

Environmental precautions Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

6.3. Methods and material for containment and cleaning up

Methods for containment Prevent further leakage or spillage if safe to do so.

Methods for cleaning up Avoid use of a filtered vacuum to clean spills of dry solids. Contain the source of the spill or leak. Clean spill area thoroughly. Collect spilled material by a method that controls dust generation.

Prevention of secondary hazards Clean contaminated objects and areas thoroughly observing environmental regulations.

6.4. Reference to other sections

Reference to other sections See section 8 for more information. See section 13 for more information.

Section 7: HANDLING AND STORAGE

7.1. Precautions for safe handling

Advice on safe handling

Minimize dust generation and accumulation. Avoid breathing dust. Avoid contact with eyes, skin and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash hands and any exposed skin after removal of PPE. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

General hygiene considerations Handle in accordance with good industrial hygiene and safety practice.

7.2. Conditions for safe storage, including any incompatibilities

Storage Conditions Store as directed by product packaging.

7.3. Specific end use(s)

Specific use(s) Pharmaceutical drug product.

Section 8: EXPOSURE CONTROLS/PERSONAL PROTECTION

8.1. Control parameters

Exposure Limits

Refer to available public information for specific member state Occupational Exposure Limits.

Daptomycin

Pfizer OEL TWA-8 Hr: 300 µg/m³

Sodium hydroxide

ACGIH OEL (Ceiling)

2 mg/m³

ACGIH TLV

Ceiling: 2 mg/m³

Austria

2 mg/m³

STEL 4 mg/m³

Bulgaria

2.0 mg/m³

Czech Republic

1 mg/m³

Ceiling: 2 mg/m³

Denmark

Ceiling: 2 mg/m³

Estonia

1 mg/m³

SAFETY DATA SHEET

Product Name Daptomycin for Injection (rapid reconstitution)
Revision date 06-Dec-2021

Page 5 / 11
Version 1.01

Finland	STEL: 2 mg/m ³
France	Ceiling: 2 mg/m ³
Hungary	2 mg/m ³
	1 mg/m ³
Ireland	STEL: 2 mg/m ³
Ceiling Limit Value	STEL: 2 mg/m ³
Latvia	2 mg/m ³
Poland	0.5 mg/m ³
	STEL: 1 mg/m ³
Romania	0.5 mg/m ³
	1 mg/m ³
	STEL: 3 mg/m ³
Slovakia	2 mg/m ³
Spain	STEL: 2 mg/m ³
Switzerland	2 mg/m ³
	STEL: 2 mg/m ³
OSHA PEL	2 mg/m ³
United Kingdom	(vacated) Ceiling: 2 mg/m ³
Citric acid	STEL: 2 mg/m ³
Czech Republic	4 mg/m ³
Germany	2 mg/m ³
	Ceiling / Peak: 4 mg/m ³
Germany	2 mg/m ³
Russia	MAC: 1 mg/m ³
Switzerland	2 mg/m ³
	STEL: 4 mg/m ³

8.2. Exposure controls

Engineering controls	Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.
Environmental exposure controls	No information available.
Personal protective equipment	Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE). Contact your safety and health professional or safety equipment supplier for assistance in selecting the correct protective clothing/equipment based on an assessment of the workplace conditions, other chemicals used or present in the workplace and specific operational processes.
Eye/face protection	Wear safety glasses or goggles if eye contact is possible. (Eye protection must meet the standards in accordance with EN166, ANSI Z87.1 or international equivalent.).
Hand protection	Impervious gloves (e.g. Nitrile, etc.) are recommended if skin contact with drug product is possible and for bulk processing operations. (Protective gloves must meet the standards in accordance with EN374, ASTM F1001 or international equivalent.).
Skin and body protection	Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations. (Protective clothing must meet the standards in accordance with EN13982, ANSI 103 or international equivalent.).
Respiratory protection	Under normal conditions of use, if the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL (e.g. particulate respirator with a half mask, P3 filter). (Respirators must meet the standards in accordance with EN140, EN143, ASTM F2704-10 or international equivalent.)

SAFETY DATA SHEET

Product Name Daptomycin for Injection (rapid reconstitution)
Revision date 06-Dec-2021

Page 6 / 11
Version 1.01

General hygiene considerations Handle in accordance with good industrial hygiene and safety practice.

Section 9: PHYSICAL AND CHEMICAL PROPERTIES

9.1. Information on basic physical and chemical properties

Physical state	Lyophilized powder
Color	Light yellow to Light brown
Odor	No information available.
Odor threshold	No information available
Molecular formula	Mixture
Molecular weight	Mixture

Property

Values

pH	4.5-5.0
Melting point / freezing point	215
Boiling point / boiling range	
Flash point	No information available
Evaporation rate	No data available
Flammability (solid, gas)	No data available
Flammability Limit in Air	
Upper flammability limit:	No data available
Lower flammability limit:	No data available
Vapor pressure	No data available
Vapor density	No data available
Relative density	No data available
Water solubility	Highly soluble:
Solubility(ies)	No data available
Partition coefficient	No data available
Autoignition temperature	No data available
Decomposition temperature	No data available
Kinematic viscosity	No data available
Dynamic viscosity	No data available
Particle characteristics	
Particle Size	No information available
Particle Size Distribution	No information available
Explosive properties	No information available

9.2. Other information

No information available

9.2.1. Information with regard to physical hazard classes

No information available

9.2.2. Other safety characteristics

No information available

Section 10: STABILITY AND REACTIVITY

10.1. Reactivity

Reactivity No data available.

10.2. Chemical stability

Stability Stable under normal conditions.

Explosion data

Sensitivity to Mechanical Impact No data available.

SAFETY DATA SHEET

Product Name Daptomycin for Injection (rapid reconstitution)
Revision date 06-Dec-2021

Page 7 / 11
Version 1.01

Sensitivity to Static Discharge No data available.

10.3. Possibility of hazardous reactions

Possibility of hazardous reactions No information available.
Hazardous polymerization Will not occur.

10.4. Conditions to avoid

Conditions to avoid Fine particles (such as dust and mists) may fuel fires/explosions.

10.5. Incompatible materials

Incompatible materials As a precautionary measure, keep away from strong oxidizers.

10.6. Hazardous decomposition products

Hazardous decomposition products No data available.

Section 11: TOXICOLOGICAL INFORMATION

11.1. Information on hazard classes as defined in Regulation (EC) No 1272/2008

Short term Accidental ingestion may cause effects similar to those seen in clinical use.
Known Clinical Effects: Adverse effects associated with therapeutic use include headache, allergic skin rash, liver effects, effects on musculoskeletal system, muscle pain, muscle weakness, neuromuscular effects. Ingestion of this material may cause effects similar to those generally seen in clinical use of antibiotics including gastrointestinal irritation, vomiting, transient diarrhea, nausea, and abdominal pain.

Acute toxicity Based on available data, the classification criteria are not met.
Serious eye damage/eye irritation Based on available data, the classification criteria are not met.
Skin corrosion/irritation Based on available data, the classification criteria are not met.
Respiratory or skin sensitization Based on available data, the classification criteria are not met.
STOT - single exposure Based on available data, the classification criteria are not met.
STOT - repeated exposure Based on available data, the classification criteria are not met.
Reproductive toxicity Based on available data, the classification criteria are not met.
Germ cell mutagenicity Based on available data, the classification criteria are not met.
Carcinogenicity Based on available data, the classification criteria are not met.
Aspiration hazard Based on available data, the classification criteria are not met.

Acute Toxicity: (Species, Route, End Point, Dose)

Daptomycin

Rat Oral Minimum Lethal Dose > 2000 mg/kg
Rat Dermal Minimum Lethal Dose > 200 mg/kg
Mouse IV Minimum Lethal Dose > 700 mg/kg
Rat IV Minimum Lethal Dose > 140 mg/kg

Sodium hydroxide

Mouse IP LD50 40 mg/kg

Citric acid

Mouse Oral LD50 5400 mg/kg

Chemical name	Oral LD50	Dermal LD50	Inhalation LC50
Sodium hydroxide	= 325 mg/kg (Rat)	= 1350 mg/kg (Rabbit)	-
Citric acid	= 3 g/kg (Rat)	> 2000 mg/kg (Rat)	-

Acute Toxicity Comments: A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

Irritation / Sensitization: (Study Type, Species, Severity)

Daptomycin

Skin irritation Rabbit Slight
Eye irritation Rabbit Slight

SAFETY DATA SHEET

Product Name Daptomycin for Injection (rapid reconstitution)
Revision date 06-Dec-2021

Page 8 / 11
Version 1.01

Sodium hydroxide

Eye Irritation Rabbit Severe

Skin Irritation Rabbit Severe

Citric acid

Eye Irritation Rabbit Severe

Skin Irritation Rabbit Mild

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Daptomycin

1 Month(s) Rat Intravenous 10 mg/kg/day LOAEL Skeletal muscle, Kidney
3 Month(s) Rat Intravenous 1 mg/kg/day LOAEL Skeletal muscle, Kidney
6 Month(s) Rat Intravenous 2 mg/kg/day LOAEL Kidney, Skeletal muscle, Bone Marrow
1 Month(s) Dog Intravenous 10 mg/kg/day LOAEL Bone Marrow, Skeletal muscle, Peripheral nervous system
3 Month(s) Dog Intravenous 1 mg/kg/day NOAEL Skeletal muscle
6 Month(s) Dog Intravenous 2 mg/kg/day NOAEL Skeletal muscle, Peripheral nervous system
1 Month(s) Monkey Intravenous 10 mg/kg/day NOAEL None identified

Reproduction & Development Toxicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Daptomycin

Reproductive & Fertility Rat Intravenous 150 mg/kg/day NOAEL Negative: Fertility, Fetotoxicity
Embryo / Fetal Development Rat Intravenous 75 mg/kg/day NOAEL Negative, Not Teratogenic
Embryo / Fetal Development Rabbit Intravenous 75 mg/kg/day NOAEL Negative, Not Teratogenic
Peri-/Postnatal Development Rat Intravenous 75 mg/kg/day NOAEL Negative: Fetotoxicity

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Daptomycin

Bacterial Mutagenicity (Ames) *Salmonella*, *E. coli* Negative
Mammalian Cell Mutagenicity Not specified Negative
Chromosome Aberration Chinese Hamster Ovary (CHO) cells Negative
In Vivo Micronucleus Mouse Negative
In Vivo Sister Chromatid Exchange Hamster Negative

Carcinogenicity None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

11.2. Information on other hazards

11.2.1. Endocrine disrupting properties

Endocrine disrupting properties No information available.

11.2.2. Other information

Other adverse effects No information available.

Section 12: ECOLOGICAL INFORMATION

Environmental Overview: Releases to the environment should be avoided. Environmental properties of the formulation have not been thoroughly investigated.

12.1. Toxicity

No information available

12.2. Persistence and degradability

Persistence and degradability No information available.

SAFETY DATA SHEET

Product Name Daptomycin for Injection (rapid reconstitution)
Revision date 06-Dec-2021

Page 9 / 11
Version 1.01

12.3. Bioaccumulative potential

Bioaccumulation No information available.

12.4. Mobility in soil

Mobility in soil No information available.

12.5. Results of PBT and vPvB assessment

PBT and vPvB assessment

Chemical name	PBT and vPvB assessment
Sodium hydroxide	The substance is not PBT / vPvB PBT assessment does not apply
Citric acid	The substance is not PBT / vPvB

12.6. Endocrine disrupting properties

Endocrine disrupting properties No information available.

12.7. Other adverse effects

No information available.

Section 13: DISPOSAL CONSIDERATIONS

13.1. Waste treatment methods

Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural wastewater and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

Section 14: TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

UN number: Not applicable
UN proper shipping name: Not applicable
Transport hazard class(es): Not applicable
Packing group: Not applicable
Environmental Hazard(s): Not applicable
Special precautions for user: Not applicable

Section 15: REGULATORY INFORMATION

SAFETY DATA SHEET

Product Name Daptomycin for Injection (rapid reconstitution)
Revision date 06-Dec-2021

Page 10 / 11
Version 1.01

15.1. Safety, health and environmental regulations/legislation specific for the substance or mixture

Daptomycin

CERCLA/SARA Section 313 de minimus %	Not Listed
California Proposition 65	Not Listed
EINECS	Not Listed
Standard for Uniform Scheduling of Medicines and Poisons (SUSMP)	Schedule 4

Sodium hydroxide

CERCLA/SARA Section 313 de minimus %	Not Listed
Hazardous Substances RQs	1000 lb
California Proposition 65	Not Listed
TSCA	Present
EINECS	215-185-5
AICS	Present
Standard for Uniform Scheduling of Medicines and Poisons (SUSMP)	Schedule 5 Schedule 6

Citric acid

CERCLA/SARA Section 313 de minimus %	Not Listed
California Proposition 65	Not Listed
TSCA	Present
EINECS	201-069-1
AICS	Present

European Union

Take note of Directive 98/24/EC on the protection of the health and safety of workers from the risks related to chemical agents at work

Authorizations and/or restrictions on use:

This product contains one or more substance(s) subject to restriction (Regulation (EC) No. 1907/2006 (REACH), Annex XVII)

Chemical name	Restricted substance per REACH Annex XVII	Substance subject to authorization per REACH Annex XIV
Sodium hydroxide - 1310-73-2	Use restricted. See item 75.	
Citric acid - 77-92-9	Use restricted. See item 75.	

Persistent Organic Pollutants

Not applicable

Ozone-depleting substances (ODS) regulation (EC) 1005/2009

Not applicable

EU - Biocides

Legend:

TSCA - United States Toxic Substances Control Act Section 8(b) Inventory

EINECS/ELINCS - European Inventory of Existing Chemical Substances/European List of Notified Chemical Substances

AICS - Australian Inventory of Chemical Substances

15.2. Chemical safety assessment

Chemical Safety Report No information available

Section 16: OTHER INFORMATION

SAFETY DATA SHEET

Product Name Daptomycin for Injection (rapid reconstitution)
Revision date 06-Dec-2021

Page 11 / 11
Version 1.01

Key or legend to abbreviations and acronyms used in the safety data sheet

Full text of H-Statements referred to under section 3

Skin corrosion/irritation-Cat.1A; H314 - Causes severe skin burns and eye damage. Specific target organ toxicity, repeated exposure-Cat.2; H373 - May cause damage to organs through prolonged or repeated exposure. Serious eye damage/eye irritation-Cat.2A; H319 - Causes serious eye irritation.

Data Sources: Publicly available toxicity information. Safety data sheets for individual ingredients.

Reason for revision New data sheet.

Revision date 06-Dec-2021

Prepared By Pfizer Global Environment, Health, and Safety

Pfizer Inc believes that the information contained in this Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.